Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6182600 | Gynecologic Oncology | 2016 | 28 Pages |
Abstract
Overall, ROMA showed well balanced diagnostic performance to differentiate EOC from benign diseases. Meaningful differences of +Â PVs and +Â LRs between HE4 and CA125 suggest that the two markers may play at least in part different roles in EOC diagnosis, with HE4 seeming to be more efficient than CA125 in ruling in EOC patients in the disease group, also in early stages tumors, both in pre and postmenopause.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Cesare Romagnolo, Antonette E. Leon, Aline S.C. Fabricio, Martina Taborelli, Jerry Polesel, Lino Del Pup, Agostino Steffan, Silvia Cervo, Antonella Ravaggi, Laura Zanotti, Elisabetta Bandiera, Franco E. Odicino, Novella Scattolo, Elisa Squarcina,